PASADENA, Calif.—Hamilton James C, Chief of Discovery/Trans Medicine at Arrowhead Pharmaceuticals, Inc. (NASDAQ:), a biotechnology company currently valued at $2.45 billion, sold a significant portion of its holdings in the company, according to a recent SEC filing. The transaction comes as the stock has declined over 50% in the past year, with InvestingPro data showing the company maintains strong liquidity with a current ratio of 6.74. The transactions, which took place on January 6, involved the sale of 32,729 shares of common stock, generating proceeds of $648,824. The shares were sold at prices ranging from $19.68 to $20.11, as part of a 10b5-1 trading plan adopted by James.
In an earlier transaction on January 4, James acquired 100,000 shares of common stock through restricted stock units, which will vest in four equal annual installments. Following these transactions, James holds 272,122 shares directly. The sales were partially made to satisfy tax withholding obligations related to the vesting of restricted stock units.
In other recent news, Arrowhead Pharma has seen significant developments in its operations and financial standing. Analysts from B. Riley maintained a Buy rating for Arrowhead, emphasizing the company’s dominance in the siRNA therapeutics market. The analysts pointed out the ongoing regulatory review of Arrowhead’s leading program, APOC3 targeting siRNA plozasiran, and potential benefits from the recent FDA approval of a similar drug, Tryngolza.
HC Wainwright raised the stock’s price target from $60.00 to $80.00 while maintaining a Buy rating, driven by Arrowhead’s recent global license and collaboration agreement with Sarepta Therapeutics (NASDAQ:). This strategic partnership is expected to significantly support Arrowhead’s financial and developmental goals. Furthermore, Arrowhead has filed a New Drug Application with the FDA for plozasiran, a therapy targeting apolipoprotein C-III for the treatment of familial chylomicronemia syndrome.
Bernstein SocGen Group lowered its price target for Arrowhead from $27.00 to $24.00, following Arrowhead’s fourth fiscal quarter 2025 update, which highlighted a significant collaboration deal with Sarepta. The company’s strategic shift will concentrate on advancing its cardiometabolic assets, such as plozasiran for FCS/SHTG and Phase 1 obesity candidates targeting INHBE and ALK7.
Piper Sandler adjusted its outlook on shares of Arrowhead Pharma, reducing the 12-month price target to $45 from the previous $62 while maintaining an Overweight rating on the stock. This followed Arrowhead’s announcement of a significant strategic partnership with Sarepta Therapeutics, involving various TRiM programs.
Finally, Chardan Capital Markets sustained its Buy rating and $60.00 stock price target for Arrowhead Pharma following a significant licensing and collaboration agreement with Sarepta Therapeutics. The deal is expected to support Arrowhead’s operations until 2028.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
